Full Product Name
AFF2 siRNA (Human)
Product Synonym Names
FMR2; OX19; AF4/FMR2 family member 2; Fragile X E mental retardation syndrome protein; Fragile X mental retardation 2 protein; FMR2P; Protein FMR-2; Protein Ox19
Product Gene Name
AFF2 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P51816
Specificity
AFF2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human AFF2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of AFF2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
AFF2 sirna
siRNA to inhibit AFF2 expression using RNA interference
Applications Tested/Suitable for AFF2 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for AFF2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001162593.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001169122.1
[Other Products]
UniProt Primary Accession #
P51816
[Other Products]
UniProt Secondary Accession #
O43786; O60215; P78407; Q13521; Q14323; Q7Z2F7; A2RTY4; B4DXD5; B7WNQ1; B7ZLD6; B7ZLD9[Other Products]
UniProt Related Accession #
P51816[Other Products]
Molecular Weight
105,116 Da
NCBI Official Full Name
AF4/FMR2 family member 2 isoform 2
NCBI Official Synonym Full Names
AF4/FMR2 family, member 2
NCBI Official Symbol
AFF2 [Similar Products]
NCBI Official Synonym Symbols
FMR2; MRX2; OX19; FMR2P; FRAXE
[Similar Products]
NCBI Protein Information
AF4/FMR2 family member 2
UniProt Protein Name
AF4/FMR2 family member 2
UniProt Synonym Protein Names
Fragile X E mental retardation syndrome protein; Fragile X mental retardation 2 protein; FMR2P; Protein FMR-2; Protein Ox19
Protein Family
AF4/FMR2 family
UniProt Gene Name
AFF2 [Similar Products]
UniProt Synonym Gene Names
FMR2; OX19; FMR2P; Protein FMR-2 [Similar Products]
UniProt Entry Name
AFF2_HUMAN
NCBI Summary for AFF2
This gene encodes a putative transcriptional activator that is a member of the AF4FMR2 gene family. This gene is associated with the folate-sensitive fragile X E locus on chromosome X. A repeat polymorphism in the fragile X E locus results in silencing of this gene causing Fragile X E syndrome. Fragile X E syndrome is a form of nonsyndromic X-linked mental retardation. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Dec 2009]
UniProt Comments for AFF2
AFF2: RNA-binding protein. Might be involved in alternative splicing regulation through an interaction with G-quartet RNA structure. Defects in AFF2 are the cause of mental retardation X- linked associated with fragile site FRAXE (MRFRAXE). A form of mild to moderate mental retardation associated with learning difficulties, communication deficits, attention problems, hyperactivity, and autistic behavior. It is associated with a fragile site on chromosome Xq28. Mental retardation is characterized by significantly below average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period. Caused either by silencing of the AFF2 gene as a consequence of a CCG expansion located upstream of this gene or by deletion within the gene. Loss of AFF2 expression is correlated with FRAXE CCG(N) expansion. Normal individuals have 6-35 copies of the repeat, whereas cytogenetically positive, developmentally delayed males have more than 200 copies and show methylation of the associated CPG island. Belongs to the AF4 family. 7 isoforms of the human protein are produced by alternative splicing.
Protein type: DNA-binding
Chromosomal Location of Human Ortholog: Xq28
Cellular Component: nuclear speck
Biological Process: learning and/or memory; regulation of RNA splicing; RNA splicing; brain development; mRNA processing
Disease: Mental Retardation, X-linked, Associated With Fragile Site Fraxe
Research Articles on AFF2
1. Partial AFF2 microduplication in a patient with auditory processing disorder, emotional impairment and macrosomia.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
